TRANSIENT RECEPTOR POTENTIAL VANILLOID-1–MEDIATED CALCIUM RESPONSES ARE INHIBITED BY THE ALKYLAMINE ANTIHISTAMINES DEXBROMPHENIRAMINE AND CHLORPHENIRAMINE

REFERENCES

• Caterina M J, Schumacher M A, Tominaga M, Rosen T A, Levine J D, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816–824
   PubMed Web of Science ®Google Scholar
• Tominaga M, Caterina M J, Malmberg A B, Rosen T A, Gilbert H, Skinner K, Raumann B E, Basbaum A I, Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998; 21: 531–543
   PubMed Web of Science ®Google Scholar
• Hwang S W, Cho H, Kwak J, Lee S Y, Kang C J, Jung J, Cho S, Min K H, Suh Y G, Kim D, Oh U. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 2000; 97: 6155–6160
   PubMed Web of Science ®Google Scholar
• Morice A H. Inhalation cough challenge in the investigation of the cough reflex and antitussives. Pulm Pharmacol 1996; 9: 281–284
   PubMedGoogle Scholar
• Laude E A, Higgins K S, Morice A H. A comparative study of the effects of citric acid, capsaicin and resiniferatoxin on the cough challenge in guinea-pig and man. Pulm Pharmacol 1993; 6: 171–175
   PubMedGoogle Scholar
• Morice A H, Geppetti P. Cough. 5: The type 1 vanilloid receptor: a sensory receptor for cough, Thorax 2004; 59: 257–258
   Google Scholar
• Gatti R, Andre E, Amadesi S, Dinh T Q, Fischer A, Bunnett N W, Harrison S, Geppetti P, Trevisani M. Protease-activated receptor-2 activation exaggerates TRPV1-mediated cough in guinea pigs. J Appl Physiol 2006; 101: 506–511
   PubMed Web of Science ®Google Scholar
• Irwin R S, Boulet L P, Cloutier M M, Fuller R, Gold P M, Hoffstein V, Ing A J, McCool F D, O'Byrne P, Poe R H, Prakash U B, Pratter M R, Rubin B K. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998; 114: 133S–181S
   PubMed Web of Science ®Google Scholar
• Morice A H, Fontana G A, Belvisi M G, Birring S S, Chung K F, Dicpinigaitis P V, Kastelik J A, McGarvey L P, Smith J A, Tatar M, Widdicombe J. ERS guidelines on the assessment of cough. Eur Respir J 2007; 29: 1256–1276
   PubMed Web of Science ®Google Scholar
• Mitchell J E, Campbell A P, New N E, Sadofsky L R, Kastelik J A, Mulrennan S A, Compton S J, Morice A H. Expression and characterization of the intracellular vanilloid receptor (TRPV1) in bronchi from patients with chronic cough. Exp Lung Res 2005; 31: 295–306
   PubMed Web of Science ®Google Scholar
• Compton S J, Cairns J A, Palmer K J, Al-Ani B, Hollenberg M D, Walls A F. A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists. J Biol Chem 2000; 275: 39207–39212
   PubMed Web of Science ®Google Scholar
• Amadesi S, Nie J, Vergnolle N, Cottrell G S, Grady E F, Trevisani M, Manni C, Geppetti P, McRoberts J A, Ennes H, Davis J B, Mayer E A, Bunnett N W. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci 2004; 24: 4300–4312
   PubMed Web of Science ®Google Scholar
• Anderson G P. TRPV1 and cough. Thorax 2004; 59: 730–731
   PubMed Web of Science ®Google Scholar
• Inoue K, Koizumi S, Fuziwara S, Denda S, Denda M. Functional vanilloid receptors in cultured normal human epidermal keratinocytes. Biochem Biophys Res Commun 2002; 291: 124–129
   PubMed Web of Science ®Google Scholar
• Denda M, Fuziwara S, Inoue K, Denda S, Akamatsu H, Tomitaka A, Matsunaga K. Immunoreactivity of VR1 on epidermal keratinocyte of human skin. Biochem Biophys Res Commun 2001; 285: 1250–1252
   PubMed Web of Science ®Google Scholar
• Mezey E, Toth Z E, Cortright D N, Arzubi M K, Krause J E, Elde R, Guo A, Blumberg P M, Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A 2000; 97: 3655–3660
   PubMed Web of Science ®Google Scholar
• Miyamoto R, Tokuda M, Sakuta T, Nagaoka S, Torii M. Expression and characterization of vanilloid receptor subtype 1 in human dental pulp cell cultures. J Endod 2005; 31: 652–658
   PubMed Web of Science ®Google Scholar
• Xin H, Tanaka H, Yamaguchi M, Takemori S, Nakamura A, Kohama K. Vanilloid receptor expressed in the sarcoplasmic reticulum of rat skeletal muscle. Biochem Biophys Res Commun 2005; 332: 756–762
   PubMed Web of Science ®Google Scholar
• Birder L A, Kanai A J, de Groat W C, Kiss S, Nealen M L, Burke N E, Dineley K E, Watkins S, Reynolds I J, Caterina M J. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci U S A 2001; 98: 13396–13401
   PubMed Web of Science ®Google Scholar
• Birder L A. TRPs in bladder diseases. Biochim Biophys Acta 2007; 1772: 879–884
   PubMed Web of Science ®Google Scholar
• Yiangou Y, Facer P, Dyer N H, Chan C L, Knowles C, Williams N S, Anand P. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 2001; 357: 1338–1339
   PubMed Web of Science ®Google Scholar
• Groneberg D A, Niimi A, Dinh Q T, Cosio B, Hew M, Fischer A, Chung K F. Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med 2004; 170: 1276–1280
   PubMed Web of Science ®Google Scholar
• Bevan S, Hothi S, Hughes G, James I F, Rang H P, Shah K, Walpole C S, Yeats J C. Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br J Pharmacol 1992; 107: 544–552
   PubMed Web of Science ®Google Scholar
• Gunthorpe M J, Hannan S L, Smart D, Jerman J C, Arpino S, Smith G D, Brough S, Wright J, Egerton J, Lappin S C, Holland V A, Winborn K, Thompson M, Rami H K, Randall A, Davis J B. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther 2007; 321: 1183–1192
   PubMed Web of Science ®Google Scholar
• Gunthorpe M J, Rami H K, Jerman J C, Smart D, Gill C H, Soffin E M, Luis Hannan S, Lappin S C, Egerton J, Smith G D, Worby A, Howett L, Owen D, Nasir S, Davies C H, Thompson M, Wyman P A, Randall A D, Davis J B. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 2004; 46: 133–149
   PubMed Web of Science ®Google Scholar
• Rami H K, Thompson M, Stemp G, Fell S, Jerman J C, Stevens A J, Smart D, Sargent B, Sanderson D, Randall A D, Gunthorpe M J, Davis J B. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006; 16: 3287–3291
   PubMed Web of Science ®Google Scholar
• Wahl P, Foged C, Tullin S, Thomsen C. Iodo-resiniferatoxin. a new potent vanilloid receptor antagonist. Mol Pharmacol 2001; 59: 9–15
   PubMed Web of Science ®Google Scholar
• Docherty R J, Yeats J C, Piper A S. Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture. Br J Pharmacol 1997; 121: 1461–1467
   PubMed Web of Science ®Google Scholar
• Liu L, Simon S A. Capsazepine, a vanilloid receptor antagonist. inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia, Neurosci Lett 1997; 228: 29–32
   Google Scholar
• Shimizu I, Iida T, Horiuchi N, Caterina M J. 5-Iodoresiniferatoxin evokes hypothermia in mice and is a partial transient receptor potential vanilloid 1 agonist in vitro. J Pharmacol Exp Ther 2005; 314: 1378–1385
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Scott B P, Nasser N, Ao H, Maher M P, Dubin A E, Swanson D M, Shankley N P, Wickenden A D, Chaplan S R. Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a TRPV1 antagonist in guinea pigs. J Pharmacol Exp Ther 2007; 323: 665–674
   PubMed Web of Science ®Google Scholar